Edward Pershing, CEO, Director, and 10% Owner of Provectus Biopharmaceuticals, Inc., filed a Form 4 on November 9, 2026, reporting the automatic conversion of an 8% Unsecured Convertible Promissory Note into Series D-1 Convertible Preferred Stock on November 6, 2026.

Key Highlights

  • Transaction date: The conversion occurred on November 6, 2026, one year after the issue date of the note, described in the filing as "the 2025 Note."
  • Note converted: An 8% Unsecured Convertible Promissory Note with outstanding principal and interest of $35,000 converted automatically into 13,216 shares of Series D-1 Convertible Preferred Stock.
  • Conversion price: The conversion was at a price per share equal to $2.862, as stated in the filing.
  • Resulting preferred holding: Following the conversion, Pershing beneficially owns 525,000 shares of Series D-1 Convertible Preferred Stock, held directly.
  • Common stock equivalence: The 13,216 newly issued preferred shares, each convertible into 10 shares of common stock, underlie 132,160 shares of common stock, according to the filing.
  • Post-transaction common stock position: Pershing beneficially owns 3,043,893 shares of common stock following the reported transaction, per the filing.
  • Automatic conversion date: The Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028, unless earlier converted, according to the filing's explanation of responses.

Provectus CEO Pershing Reports Note-to-Preferred Conversion Under 2025 Financing

According to the Form 4 filed with the SEC on November 9, 2026, Edward Pershing, who serves as CEO, Director, and 10% Owner of Provectus Biopharmaceuticals, Inc. (OTC:PVCT), reported that the 8% Unsecured Convertible Promissory Note referred to in the filing as "the 2025 Note" automatically converted into 13,216 shares of Series D-1 Convertible Preferred Stock on November 6, 2026. The filing states that the conversion price per share was $2.862, and that the outstanding principal and interest of the 2025 Note totaled $35,000.

The filing explains that the 2025 Note "was issued pursuant to the Issuer's 2025 Financing" and that the reporting person could have voluntarily elected to convert the note at any time while it was outstanding. However, the note automatically converted on the date that was twelve months after its issue date. The transaction code recorded is "M," denoting a conversion of a derivative security. The price of the derivative security following conversion is listed as $0, and the Series D-1 Convertible Preferred Stock position of 525,000 shares is held directly.

The filing further discloses that each share of Series D-1 Preferred Stock is convertible into 10 shares of the issuer's common stock, par value $0.001 per share, and that the Series D-1 Convertible Preferred Stock will automatically convert into common stock on December 31, 2028, unless earlier converted in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. Following all reported transactions, Pershing's direct beneficial ownership of common stock stands at 3,043,893 shares, as stated in the filing.

What Was Disclosed

The filing reports that CEO and Director Edward Pershing's 8% Unsecured Convertible Promissory Note automatically converted on November 6, 2026, into 13,216 shares of Series D-1 Convertible Preferred Stock at $2.862 per share, bringing his total direct preferred holding to 525,000 shares.